NZ757221A - Crystalline forms of diazabicyclooctane derivative and production process thereof - Google Patents

Crystalline forms of diazabicyclooctane derivative and production process thereof

Info

Publication number
NZ757221A
NZ757221A NZ757221A NZ75722114A NZ757221A NZ 757221 A NZ757221 A NZ 757221A NZ 757221 A NZ757221 A NZ 757221A NZ 75722114 A NZ75722114 A NZ 75722114A NZ 757221 A NZ757221 A NZ 757221A
Authority
NZ
New Zealand
Prior art keywords
diazabicyclooctane derivative
production process
crystalline forms
diazabicyclooctane
derivative
Prior art date
Application number
NZ757221A
Other languages
English (en)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of NZ757221A publication Critical patent/NZ757221A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ757221A 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof NZ757221A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
NZ743374A NZ743374A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof

Publications (1)

Publication Number Publication Date
NZ757221A true NZ757221A (en) 2021-12-24

Family

ID=52813113

Family Applications (5)

Application Number Title Priority Date Filing Date
NZ757220A NZ757220A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ743374A NZ743374A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ757222A NZ757222A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ757221A NZ757221A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ719568A NZ719568A (en) 2013-10-08 2014-10-08 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NZ757220A NZ757220A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ743374A NZ743374A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof
NZ757222A NZ757222A (en) 2013-10-08 2014-10-08 Crystalline forms of diazabicyclooctane derivative and production process thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ719568A NZ719568A (en) 2013-10-08 2014-10-08 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Country Status (22)

Country Link
US (5) US10131665B2 (enExample)
EP (4) EP3067355B1 (enExample)
JP (3) JP6617029B2 (enExample)
KR (2) KR102487297B1 (enExample)
CN (2) CN105612159A (enExample)
AR (4) AR097971A1 (enExample)
AU (1) AU2014332960B2 (enExample)
BR (2) BR122022016622B1 (enExample)
CA (2) CA2926071C (enExample)
DK (1) DK3067355T3 (enExample)
ES (2) ES2842225T3 (enExample)
HK (1) HK1219479A1 (enExample)
HU (1) HUE051925T2 (enExample)
IL (2) IL244969B (enExample)
MX (2) MX361659B (enExample)
MY (1) MY199066A (enExample)
NZ (5) NZ757220A (enExample)
RU (1) RU2695219C2 (enExample)
SG (1) SG11201602723RA (enExample)
TW (1) TWI673269B (enExample)
WO (1) WO2015053297A1 (enExample)
ZA (1) ZA201602054B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
AU2014324302B2 (en) 2013-09-24 2018-02-15 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivative and intermediary body thereof
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
CA2969192C (en) * 2014-12-05 2023-02-28 Meiji Seika Pharma Co., Ltd. A process for producing crystals of a diazabicylooctane derivative and a stable lyophilized composition thereof
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
US11299467B2 (en) 2017-07-21 2022-04-12 Antabio Sas Chemical compounds
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
US10682413B2 (en) 2017-09-27 2020-06-16 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
JP7523354B2 (ja) * 2018-09-21 2024-07-26 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
CN115315297B (zh) * 2020-07-13 2024-06-04 日本碍子株式会社 精制方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (enExample) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (enExample) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2231667B1 (en) * 2008-01-18 2013-09-04 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SG191320A1 (en) 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
ES2560404T3 (es) * 2011-06-17 2016-02-18 Astrazeneca Ab Procesos para preparar compuestos heterocíclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
BR112013032974A2 (pt) 2011-08-30 2016-09-06 Wockhardt Ltd "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
EP2961751B1 (en) * 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
AU2014324302B2 (en) 2013-09-24 2018-02-15 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivative and intermediary body thereof
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
BR112016022437A2 (pt) 2014-03-29 2017-08-15 Wockhardt Ltd Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
CA2969192C (en) 2014-12-05 2023-02-28 Meiji Seika Pharma Co., Ltd. A process for producing crystals of a diazabicylooctane derivative and a stable lyophilized composition thereof

Also Published As

Publication number Publication date
JP2020007366A (ja) 2020-01-16
NZ743374A (en) 2021-12-24
CN105612159A (zh) 2016-05-25
US20220348578A1 (en) 2022-11-03
US11414417B2 (en) 2022-08-16
JPWO2015053297A1 (ja) 2017-03-09
MY199066A (en) 2023-10-12
IL289275B (en) 2022-10-01
KR102487297B1 (ko) 2023-01-12
ES2842225T3 (es) 2021-07-13
HK1250030A1 (en) 2018-11-23
KR20160065871A (ko) 2016-06-09
RU2019115119A (ru) 2019-05-29
CA3110803C (en) 2022-09-27
RU2695219C2 (ru) 2019-07-22
EP3067355A4 (en) 2017-04-26
WO2015053297A1 (ja) 2015-04-16
IL289275A (en) 2022-02-01
EP3067355B1 (en) 2020-12-16
TWI673269B (zh) 2019-10-01
CA2926071C (en) 2021-11-09
DK3067355T3 (da) 2021-01-04
US20200181143A1 (en) 2020-06-11
EP3299370A1 (en) 2018-03-28
RU2016116501A (ru) 2017-11-15
US10131665B2 (en) 2018-11-20
US20190031659A1 (en) 2019-01-31
JP6995810B2 (ja) 2022-01-17
IL289275B2 (en) 2023-02-01
JP6617029B2 (ja) 2019-12-04
IL244969B (en) 2022-01-01
US20160272641A1 (en) 2016-09-22
HK1219479A1 (zh) 2017-04-07
EP3613741A1 (en) 2020-02-26
BR112016006266A2 (enExample) 2017-08-22
RU2019115119A3 (enExample) 2022-04-26
BR112016006266B1 (pt) 2022-11-16
EP3299370B1 (en) 2021-11-24
SG11201602723RA (en) 2016-05-30
BR122022016622B1 (pt) 2023-11-07
KR102388529B1 (ko) 2022-04-20
AR132029A2 (es) 2025-05-21
MX383661B (es) 2025-03-14
NZ757220A (en) 2021-12-24
MX361659B (es) 2018-12-13
NZ757222A (en) 2021-12-24
AU2014332960A1 (en) 2016-05-26
ZA201602054B (en) 2019-06-26
NZ719568A (en) 2018-06-29
JP2021193107A (ja) 2021-12-23
AR097971A1 (es) 2016-04-20
TW201605855A (zh) 2016-02-16
JP7182677B2 (ja) 2022-12-02
AU2014332960B2 (en) 2018-03-29
HUE051925T2 (hu) 2021-04-28
AR132028A2 (es) 2025-05-21
ES2901198T3 (es) 2022-03-21
KR20220054694A (ko) 2022-05-03
CA3110803A1 (en) 2015-04-16
CA2926071A1 (en) 2015-04-16
MX2016004506A (es) 2016-06-16
EP3613740A1 (en) 2020-02-26
US10604522B2 (en) 2020-03-31
US20250059191A1 (en) 2025-02-20
EP3067355A1 (en) 2016-09-14
AR132030A2 (es) 2025-05-21
US12221443B2 (en) 2025-02-11
CN111153903A (zh) 2020-05-15
RU2016116501A3 (enExample) 2018-07-12
IL244969A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
NZ757221A (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
IL289910A (en) A method for preparing allulose crystals
MX2022009300A (es) Derivado de quinolina muy puro y metodo para su produccion.
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
EP3028994A4 (en) Silicon carbide powder and method for producing silicon carbide single crystal
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
EP3192898A4 (en) Method for producing silicon carbide crystals and crystal production device
IN2013MU00646A (enExample)
IL265536A (en) A method for the production of a crystalline form of the a modification of calcobuterol
EA201591530A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
AU2014371081A1 (en) Polyoxalates and a Process for the Production Thereof
AU2016299728A8 (en) Substituierted Furano-/Thienocycloalkylamino-2-Pyrimidine derivatives and use thereof for controlling undesired plant growth
MY201222A (en) Synthesis of morin and morin derivatives
WO2016016774A8 (en) Crystalline forms of canagliflozin
IL231677A (en) 5-Hydroxy-H1 Crystal-Imidazole-4-Carboxamide 4./3 Hydrate and Method of Manufacturing
PL2967095T3 (pl) Sposób wytwarzania serów o zmienionej strukturze
IN2014DN08198A (enExample)
AR107441A1 (es) Forma cristalina de cobicistat
EP3221909A4 (fr) Reseau d'anatase nanometrique stabilize par des lacunes cationiques, procedes pour leur preparation et leurs utilisations
LT2860175T (lt) 4,4,7-trifluor-1,2,3,4-tetrahidro-5h-1-benzazepino junginio ir jo sintezei skirto tarpinio junginio gamybos būdas
SG11201509022XA (en) METHOD FOR PRODUCING α-SUBSTITUTED CYSTEINE OR SALT THEREOF OR INTERMEDIATE FOR SYNTHESIS OF α-SUBSTITUTED CYSTEINE

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2023 BY CPA GLOBAL

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2024 BY CPA GLOBAL

Effective date: 20230831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250828